Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 1998

View Archived Issues

Calypte Biomedical to acquire assets of Cambridge Biotech

AMBI seeks partners to develop injectable nisin for treatment of hospital-acquired infections

Abgenix initiates a phase I/II clinical trial in patients with psoriasis

Bausch & Lomb to manufacture Lidakol for treatment of oral-facial herpes

Ascent to promote Warner-Lambert's Omnicef

AxyS initiates phase I studies of APC-2059 for treatment of acute inflammatory bowel disease

IntraBiotics receives milestone payment from Pharmacia & Upjohn

Adozelesin displays marginal efficacy in previously untreated metastatic breast cancer

Significant protection against ischemic injury in cortex of rats primed with estradiol

U.S. patent covers transgenically produced rhATIII

First clinical trial of human gene therapy for hemophilia begins

Genzyme General receives FDA approval for Thyrogen

Dyax and Genzyme General to develop new antiinflammatory treatment

Final marketing application filed for Ampligen in E.U.

rNAPc2 enters phase II trials in U.S. and Europe

Sanofi, Synthelabo plan another significant European drug company merger

Cytogen submits NDS for ProstaScint for approval in Canada and highlights new clinical data

MedImmune and Pasteur Merieux Connaught develop second-generation Lyme disease vaccine

Harris FRC establishes safety of candidate antiepileptic drug in volunteer studies

Second-generation PD diagnostic enters preclinical development at BLSI

Accutin, an RGD-containing peptide with angiogenesis-inhibitory activity

Health Canada approves first new incontinence medication in over a decade

Agents for ulcers synthesized and evaluated at Shiseido

American Home Products describes preferential COX-2 inhibitors

New HIV protease inhibitors in development at Monsanto

Pharmacokinetic studies support chronic dosing of FK-143

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...